Synergy was most prominent in DLBCL and follicular lymphoma lines and was seen with both approved and emerging drugs used to treat B-cell malignancies, including dexamethasone, inhibitors of the B-cell receptor signaling pathway, such as ibrutinib, and the BCL-2 inhibitor venetoclax (Fig 2B). The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.